RESECTABLE HEPATOCELLULAR CARCINOMA WITH HIGH RISK OF RECURRENCE

Clinical trials for RESECTABLE HEPATOCELLULAR CARCINOMA WITH HIGH RISK OF RECURRENCE explained in plain language.

Never miss a new study

Get alerted when new RESECTABLE HEPATOCELLULAR CARCINOMA WITH HIGH RISK OF RECURRENCE trials appear

Sign up with your email to follow new studies for RESECTABLE HEPATOCELLULAR CARCINOMA WITH HIGH RISK OF RECURRENCE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New combo therapy aims to shrink tumors before liver cancer surgery

Disease control Recruiting now

This study is testing a three-part treatment given before surgery for patients with liver cancer that has a high chance of coming back. Doctors combine a procedure that delivers chemotherapy directly to the tumor (TACE) with two immunotherapy drugs (atezolizumab and bevacizumab).…

Matched conditions: RESECTABLE HEPATOCELLULAR CARCINOMA WITH HIGH RISK OF RECURRENCE

Phase: PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control

Last updated Mar 17, 2026 13:08 UTC

RESECTABLE HEPATOCELLULAR CARCINOMA WITH HIGH RISK OF RECURRENCE

Get alerted when new RESECTABLE HEPATOCELLULAR CARCINOMA WITH HIGH RISK OF RECURRENCE trials appear

New combo therapy aims to shrink tumors before liver cancer surgery